Skip to main content
Cipla Ltd. logo

Cipla Ltd. — Investor Relations & Filings

Ticker · CIPLA ISIN · INE059A01026 LEI · 335800KMJJYEDDK82Q34 BSE.NS Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2019-10-14 Regulatory Filings
Country IN India
Listing BSE.NS CIPLA

About Cipla Ltd.

https://www.cipla.com/

Cipla Ltd. is a global pharmaceutical company focused on the development, manufacturing, and marketing of a wide range of generic and branded medicines. The company maintains a diverse portfolio of over 1,500 products across various therapeutic areas, including respiratory, anti-retroviral, urology, cardiology, anti-infective, and central nervous system treatments. It is recognized for its leadership in respiratory care and its historical role in making HIV/AIDS treatment affordable through the introduction of low-cost antiretroviral drugs. Operating with a strong emphasis on research and development, the firm utilizes advanced technology to produce complex generics and drug delivery systems. Its global footprint spans multiple continents, serving healthcare providers and patients in numerous international markets through a robust supply chain and manufacturing infrastructure.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document text contains only placeholders for images and no substantive text or financial data. The true document length is only 133 characters, indicating it is extremely short and contains no report content. There is no indication of any report, announcement, or filing type. Given the lack of content, this document does not fit any specific report category and defaults to Regulatory Filings (RNS) as a fallback category.
2019-10-14 English
CIPLA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2019 ,inter alia, to consider and approve A meeting of the Board of Directors ....
Regulatory Filings Classification · 100% confidence The document text contains only placeholders for images and no substantive text or financial data. The true document length is only 133 characters, indicating it is extremely short and contains no report content. There is no indication of any report, announcement, or filing type. Given the lack of content, this document does not fit any specific report category and defaults to Regulatory Filings (RNS) as a fallback category for miscellaneous filings without substantive information.
2019-10-14 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges and a regulatory body, informing about the completion of a USFDA cGMP inspection at Cipla's manufacturing facility. It mentions the inspection dates, observations, and the company's intention to respond. The document is short (1303 characters) and serves as an announcement of an event rather than a detailed report or financial disclosure. It does not contain financial data, management discussion, or detailed audit information. It is a regulatory announcement related to compliance and inspection results, fitting best under Regulatory Filings (RNS) as it does not fit other specific categories like Audit Report or Legal Proceedings Report.
2019-09-28 English
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the United States Food and Drug Administration (USFDA) ....
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges and a regulatory body, informing about the completion of a USFDA cGMP inspection at Cipla's manufacturing facility. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure obligations. The document is brief (1303 characters) and serves as an announcement of an event (inspection completion and observations) rather than a detailed report or financial statement. There is no financial data, no detailed audit or management discussion, no voting results, or other report content. Therefore, it fits best as a Regulatory Filing (RNS), which is a general regulatory announcement and a fallback category for miscellaneous filings that do not fit other specific categories.
2019-09-28 English
Press Release
Regulatory Filings Classification · 90% confidence The document is a press release announcing the launch of a pharmaceutical product (Daptomycin for Injection) by Cipla and its subsidiary Cipla USA. It contains no financial statements, no regulatory filings, no voting results, no management or board changes, no earnings data, and no detailed report content. The document is a corporate announcement about a product launch, which does not fit into any of the specific financial or regulatory filing categories such as Annual Report, Earnings Release, or Regulatory Filings. Given the nature of the content and the absence of financial or regulatory report elements, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2019-09-25 English
Press Release - Cipla announces the launch of Daptomycin for injection, 500 mg/vial, single-dose vials (for intravenous use only)
Regulatory Filings
2019-09-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.